Company Filing History:
Years Active: 2020-2021
Title: Konstantinos Karabelas: Innovator in Pharmaceutical Chemistry
Introduction
Konstantinos Karabelas is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that inhibit specific kinase activities. With a total of 2 patents, his work is recognized for its potential impact on treating various clinical conditions.
Latest Patents
Karabelas's latest patents include a compound known as (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one, which serves as a phosphatidylinositol 3-kinase inhibitor. This compound is designed to inhibit phosphatidylinositol 3-kinase (PI3K) activity, which is crucial in various cellular processes. Additionally, he has developed inhibitors of phosphatidylinositol 3-kinase gamma, which are aimed at treating respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
Career Highlights
Karabelas is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on innovative solutions in drug development, contributing to the advancement of therapeutic options for patients.
Collaborations
Throughout his career, Karabelas has collaborated with esteemed colleagues, including Mickael Mogemark and Jens Petersen. These collaborations have fostered a productive environment for research and innovation in the pharmaceutical sector.
Conclusion
Konstantinos Karabelas is a prominent figure in pharmaceutical innovation, with a focus on developing compounds that address critical health issues. His contributions through patents and collaborations highlight his commitment to advancing medical science.